Aldosterone is thought to modulate renal fibrosis, in part, through increasing plasminogen activator inhibitor type 1 (PAI-1), a major inhibitor of ECM degradation.
INTRODUCTION
Activation of the renin-angiotensin-aldosterone system (RAAS) and generation of angiotensin II (Ang II) play a crucial role in fibrotic renal disease through both pressuredependent and pressure-independent mechanisms (29) . Ang II blockade has been a great therapeutic breakthrough for a variety of renal diseases. However, accumulating evidence from both clinical and laboratory research has suggested that halting renal fibrosis can not be achieved by angiotensin converting enzyme inhibitors (ACEi) or Ang II receptor blockers (ARB) alone or in combination given at maximal dosages and correct frequency (14, 18, 37, 43) . One reason could be the effects of aldosterone.
Elevated plasma aldosterone levels are usually observed in patients chronically treated with ACEi by a phenomenon known as "aldosterone escape" (48). The elevated aldosterone level is seen not only in plasma but also in tissue due to alternative pathways of Ang II generation including chymase and chathepsin G (34) . Although it was once thought that aldosterone acts primarily as a circulating hormone involved in the regulation of sodium excretion through mineralocorticoid receptor (MR)-dependent mechanisms, evidence has been mounting to suggest that aldosterone also contributes to inflammatory and fibrotic effects that were previously attributed solely to Ang II (16, 53). In fact, aldosterone receptor blockers have been shown to decrease mortality in patients with congestive heart failure, to improve endothelial function, to reduce circulating markers of collagen turnover and to decrease microalbuminuria (17, 44, 45, 50) . Addition of spironolactone to ACEi markedly reduced proteinuria in patients with renal failure and in patients with diabetes (11, 46) . In rats, studies have consistently 4 demonstrated that aldosterone causes glomerular injury, interstitial inflammation and fibrosis in hypertensive rat kidneys (5) . Aldosterone receptor blockers markedly ameliorated glomerular and/or tubulointerstitial injury in several models of nephropathy including spontaneously hypertensive stroke-prone rats, diabetic rats, nephritic rats and chronic cyclosporine-induced nephrotoxic rats (20-22, 39, 42, 47) . Moreover, MR blockade not only reduced the development of glomerulosclerosis but also induced regression of existing glomerulosclerosis in rats after 5/6 nephrectomy (1). These studies together not only emphasized the beneficial effect of MR antagonism in progressive renal diseases but also suggested that the profibrotic effects of aldosterone might be independent of other components of the RAAS. Thus the aldosterone escape phenomenon occurring during long-term use of Ang II blocker may, in fact, contribute to the limited effectiveness of this therapy. Understanding the mechanisms underlying Ang II-independent actions of aldosterone may guide the use of combination therapy with Ang II and aldosterone blockers in these patients.
One possible mechanism by which aldosterone may contribute to renal fibrosis is through induction of plasminogen activator inhibitor-1 (PAI-1) expression. Aldosterone was first observed to induce PAI-1 expression in vascular smooth muscle cells and then in endothelial cells, cardiomyocytes, and recently in mesangial cells (8, 12, 56) .
Treatment with an MR antagonist decreased PAI-1 expression in the heart of Ang II/NGnitro-L-arginine methyl ester-treated mice (8) and in the rat kidney following radiation injury (9), strepotozocin-induced diabetic nephropathy (20) and 5/6 nephrectomy (1).
Moreover, PAI-1 deficiency protected against aldosterone/salt-induced glomerular Page 4 of 41 5 hypertrophy and injury (35) . Elevated PAI-1, the major inhibitor of plasminogen activators, is thought to inhibit plasmin generation and activation of matrix degrading metalloproteinases, thereby decreasing ECM degradation and enhancing ECM accumulation in the kidney (26) . It is likely that PAI-1 mediates aldosterone-induced profibrotic effects in renal disease.
Several other key modulators of renal fibrosis also induce PAI-1. Transforming growth factor-beta1 (TGF-ß1) increases PAI-1 production by cultured glomeruli, and overexpression of TGF-ß in disease is associated with increased PAI-1 expression (15, 43, 51) . Ang II upregulates PAI-1 expression by mechanisms both independent of and dependent on TGF-ß (30). Therapeutic strategies aimed to reduce Ang II or TGF-ß also reduce PAI-1 overexpression (43, 55) . Recently, renin was found to induce PAI-1 expression via a renin receptor-mediated, Ang II-independent mechanism partially mediated by TGF-ß (27) . The increasingly recognized connection between aldosterone and progressive kidney disease stimulated us to ask whether aldosterone, like Ang II and renin, induces TGF-ß, whether aldosterone induces PAI-1 expression through a TGF-ß1-mediated pathway, and whether aldosterone exerts a synergistic effect with TGF-1 on PAI-1 overexpression thereby leading to decreased ECM degradation.
We chose to study the profibrotic action of aldosterone on MCs and renal fibroblasts since abundant MRs are present, particularly in the cytoplasm of MCs (38, 40) and because they are key cell types involved in glomerular and interstitial fibrosis.
Page 5 of 41 6 In order to study ECM degradation, we developed an in vitro system utilizing MCs cultured on extracellular matrices produced by MCs themselves, which contain similar matrix components to those seen in vivo (23). Utilizing this system, we confirmed that ECM degradation by cultured rat MC or NRK-49F was dependent upon added plasminogen and was mediated by plasmin (23, 54). The fact that addition of uPA or tPA was not required for matrix degradation confirmed other published studies showing that MCs or NRK-49F cells produce uPA and tPA. ECM degradation by cultured rat MCs or NRK-49F cells, thus, is dependent on the presence of a functional PA/plasminogen/plasmin system (3, 4) . As the primary in vivo inhibitor of the plasminogen activators tPA and uPA, PAI-1 tightly regulates this system (25) . Increased PAI-1 levels can dramatically reduce plasmin generation thereby decreasing plasmindependent extracellular matrix degradation defining a mechanistic path for increasing matrix accumulation in progressive kidney disease.
METHODS

Materials
Aldosterone and spironolactone were supplied by Acros Organics (New Jersey, USA).
Recombinant human TGF-1, 1D11 used as the pan-specific TGF-neutralization antibody and 13C4 used as control IgG were obtained from R&D Systems (Minneapolis, MN, USA). Unless otherwise indicated, materials, chemicals or culture media needed were purchased from Sigma Chemical Co (St. Louise, MO, USA).
Cell culture
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Primary MCs were derived from intact rat glomeruli of four-to-six-week-old Wistar rats and characterized according to published methods (30). Cells were used between passages 4 and 7 and were maintained in RPMI 1640 medium supplemented with 20% FBS (Hyclone Laboratory, Logan, UT, USA), 100 U/mL penicillin, 100µg/mL streptomycin, 0.1 U/mL insulin, 25 mM HEPES buffer at 37°C in a 5% CO 2 incubator.
Subconfluent cells seeded on six-well plates were made quiescent in serum-free RPMI 1640 medium for 48 h prior to experimental studies. 
RNA-preparation and Northern hybridization
Total RNA of cultured cells was extracted by a guanidinium isothiocyanate method this ratio was set at unity for normal control samples and other lanes on the same gel were expressed as fold increases over this value.
PAI-1 Western blot
After treatment, the cultured cell supernatant was harvested and centrifuged 
Measurement of ECM degradation
Production of radioactive matrices. Rat MC matrices were obtained as described Degradation of the matrices by NRK-49F cells was measured by a similar procedure except DMEM with 5% FBS was used for culture and DMEM with 0.2% lactalbumin hydrolyzate was used for treatment instead of RPMI 1640.
Statistical analysis
Data are expressed as mean±SEM. Statistical analyses of differences between the groups were performed by ANOVA and subsequent Student-Newman-Keuls or Dunnett testing for multiple comparisons. Comparisons with a P value < 0.05 were considered significantly different. Triplicate wells were analyzed for each experiment, and each experiment was performed independently a minimum of three times. Figure 5B ). Figure 6 shows that a 3 h incubation with 1D11 (20 µg/mL) had no effect on aldosterone-induced increases in PAI-1 mRNA ( Figure 6A) . However, at 24 h, 1D11 significantly reduced PAI-1 mRNA by 26.1% ( Figure 6B ) and PAI-1 protein by 14 18.3% after 48 h treatment ( Figure 6C ). These results indicate that aldosterone-induced PAI-1 overexpression by both MCs and NRK49F is partially mediated by TGF-1. M was co-treated with 20pg/mL TGF-1, they yielded even a greater effect on PAI-1 mRNA and protein expression than either compound alone. These results suggest that aldosterone and TGF-1 added together produce synergistic effects on PAI-1 production.
Synergistic
Synergistic effect of TGF-1 and aldosterone on ECM degradation by renal MCs and NRK-49F cells
As was expected, aldosterone or TGF-ß1 alone inhibited MC matrix degradation by 39% and 49% and NRK-49F cell matrix degradation by 21% and 23%, respectively in the presence of 4 µg/mL exogenous plasminogen (P < 0.001) (Figure 9 ). Strikingly, has been reported to target renal fibroblasts via binding to the MR since renal fibroblasts also express MR mRNA and protein (38) . Addition of aldosterone to cultured renal fibroblasts induced collagen gene expression and synthesis, effects blocked by eplerenone (38) . In the present study, addition of aldosterone to renal fibroblasts significantly reduced ECM degradation. Moreover, decreased ECM degradation in aldosterone-treated cells was associated with increased expression of PAI-1 and these increases were prevented by spironolactone. Therefore, aldosterone appears to contribute to interstitial matrix accumulation by both increased matrix production and decreased degradation.
TGF-ß has a well-established role in a wide range of renal injuries. Many molecules upregulate TGF-ß expression, particularly in the RAAS (6, 27) . Whether aldosterone also stimulates TGF-ß is receiving attention. Aldosterone infusion for 3 days increased urinary TGF-ß excretion (28) . This effect is independent of the steroid's effects on potassium and extracellular volume expansion since hypertension and renal injury were not present in 3 days. A number of studies have shown that treatment of MCs in vitro with aldosterone significantly enhanced TGF-ß1 secretion and activation via MR. No data on mRNA levels were given (22, 32, 56) . Spironolactone administration decreased Page 17 of 41 18 elevated renal TGF-ß1 mRNA in rats with chronic cyclosporine nephrotoxicty and renal TGF-ß1 protein production in rats with type 1 diabetes or experimental glomerulonephritis (20, 21, 42 ). In our in vitro work we have been unable to show anything but small increases in TGF-ß expression in response to aldosterone treatment.
Aldosterone at high concentration (10 -6 M) increased fibroblast TGF-ß1 mRNA less than 100% after 48 h incubation (Figure 4) . Similarly, aldosterone concentrations less than 10 -5
M only slightly increased TGF-ß1 mRNA expression by 20% in MCs. TGF-ß1
protein levels became significant only at 48 h after treatment ( Figure 2 ). Therefore, our data suggest that aldosterone upregulates PAI-1 expression much more than TGF-ß in these cells. It is not surprising that aldosterone-induced PAI-1 expression is only partially mediated by TGF-ß. This result is compatible with prior data in integrin ß6 deficient mice where aldosterone induced renal PAI-1 expression and fibrosis through a TGF-ß-independent pathway because ß6 deficiency impaired TGF-ß activation and its subsequent cellular actions (36) . Aldosterone was demonstrated to stimulate collagen gene expression and synthesis via activation of cellular ERK1/2 signaling in rat renal fibroblasts (38) . Further studies are required to determine if aldosterone-stimulated PAI-1 expression is mainly regulated by a mitogen-activated protein kinase in renal cells.
Of note is where there is fibrosis, there is overexpression of TGF-ß in both animal models and humans (7, 24) . It is relevant that we could not suppress elevated TGF-ß production by more than about 50% in experimental nephritis whether maximally effective doses of enalapril or losartan were used alone or in combination (43) . The present data suggest that increased aldosterone due to "aldosterone escape" could be Page 18 of 41 19 another important contributor to renal fibrosis because aldosterone interacts synergistically with TGF-ß to increase PAI-1 overexpression and subsequently inhibit ECM degradation. If it acts in vivo, this synergistic effect may explain the beneficial effects of combination therapy with an Ang II blocker and an aldosterone blocker that have been observed in patients with heart failure, diabetic nephropathy and nephritic range albuminuria (11, 44, 46, 49) and in animal models with hypertension and glomerulonephritis (2, 31, 41).
In conclusion, the present experiments show that aldosterone-induced PAI-1 overexpression by both MCs and NRK49F is partially mediated by TGF-1. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
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